Online inquiry

IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9098MR)

This product GTTS-WQ9098MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&PMEL gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000733.4; NM_001200053.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 6490
UniProt ID P07766; P40967
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ9098MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4744MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BPS-804
GTTS-WQ7325MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ2133MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALD-403
GTTS-WQ15754MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ11415MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ4778MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ9099MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMCgp100
GTTS-WQ11011MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MCLA-117
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW